ClinicalTrials.gg

Program

JNJ-89853413

A development code.

Its studies are mostly in Leukemia, Myeloid, Acute, led by Johnson & Johnson.

Furthest: phase 1, since Sep 26, 20241 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson10 open or runningphase 1since Sep 26, 2024Sep 26, 2024none ahead
  • Named in Johnson & Johnson’s own pipeline as JNJ-3413, phase 1, as of Oct 13, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2024First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT06618001 · 64 enrolled · Canada, Spain, United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06618001Leukemia, Myeloid, Acute · Canada, Spain, United Kingdom1CompletedSep 1, 202664

How it is read

Names in the registry

  • “JNJ-89853413”, 1 entry

Codes read as this program: JNJ89853413.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.